On May 16, the FDA approved Fragmin (dalteparin sodium) injection to reduce the recurrence of symptomatic venous thromboembolism (VTE) in pediatric patients 1 month of age and older.…
Reader Survey
Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.